onclive· 2mo ago
save<![CDATA[Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)]]>
May 14, 2026read original ↗
<![CDATA[Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.]]>
The original article is no longer reachable from this URL.
read full article on onclive ↗🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that